NASDAQ:MDRX

Veradigm (MDRX) Stock Price, News & Analysis

$7.95
+0.27 (+3.52%)
(As of 04:35 PM ET)
Today's Range
$7.65
$8.00
50-Day Range
$6.13
$8.52
52-Week Range
$5.01
$14.09
Volume
822,353 shs
Average Volume
3.89 million shs
Market Capitalization
$868.62 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.25

Veradigm MarketRank™ Stock Analysis

Analyst Rating
Hold
2.20 Rating Score
Upside/​Downside
41.5% Upside
$11.25 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-0.62
Upright™ Environmental Score
News Sentiment
0.44mentions of Veradigm in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
11.43%
From $0.70 to $0.78 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.20 out of 5 stars

Business Services Sector

211th out of 303 stocks

Computer Integrated Systems Design Industry

16th out of 34 stocks

MDRX stock logo

About Veradigm Stock (NASDAQ:MDRX)

Veradigm Inc., a healthcare technology company, provides information technology solutions and services to healthcare organizations in the United States, Canada, and internationally. It offers electronic health records (EHR), information connectivity, private cloud hosting, outsourcing, analytics, patient access, and population health management solutions. The company operates through two segments, Hospitals and Large Physician Practices, and Veradigm. The Hospitals and Large Physician Practices segment provides integrated clinical and financial management solutions, which primarily include EHR-related software; and related installation, support and maintenance, outsourcing, private cloud hosting, and revenue cycle management services. The Veradigm segment offers payer and life sciences solutions, which are primarily targeted at payers, life sciences companies, and other healthcare stakeholders; and software applications for patient engagement and EHR software to single-specialty, and small and mid-sized physician practices, including related clinical, financial, administrative, and operational solutions. Its solutions enable clients to transition, analyze, and coordinate care, and enhance the healthcare delivery across the care community. The company serves physicians, hospitals, governments and militaries, health systems, health plans, life-sciences companies, retail clinics, surgery centers, retail pharmacies, pharmacy benefit managers, insurance companies, employer wellness clinics, consumers, lab companies, urgent care facilities, and venture capital firms, as well as post-acute organizations, such as home health and hospice agencies. The company was formerly known as Allscripts Healthcare Solutions, Inc. and changed its name to Veradigm Inc. in January 2023. Veradigm Inc. was founded in 1986 and is headquartered in Chicago, Illinois.

MDRX Stock Price History

MDRX Stock News Headlines

Veradigm (NASDAQ:MDRX) Coverage Initiated at StockNews.com
The Best AI Stock to Own in the World Today is Trading for Just $25
“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.
Veradigm (NASDAQ:MDRX) Stock Price Up 9.3%
Veradigm (NASDAQ:MDRX) Shares Gap Up to $7.45
StockNews.com Begins Coverage on Veradigm (NASDAQ:MDRX)
The Best AI Stock to Own in the World Today is Trading for Just $25
“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.
MDRX Apr 2024 2.500 put
Veradigm Completes Acquisition of ScienceIO
Market Whales and Their Recent Bets on MDRX Options
Veradigm Receives Expected Delisting Notice from Nasdaq
Veradigm to Acquire ScienceIO
See More Headlines
Receive MDRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Veradigm and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/04/2021
Today
4/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Industry
Computer integrated systems design
Sub-Industry
Health Care Technology
Current Symbol
NASDAQ:MDRX
CUSIP
01988P10
Employees
8,000
Year Founded
1986

Price Target and Rating

Average Stock Price Target
$11.25
High Stock Price Target
$13.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+41.5%
Consensus Rating
Hold
Rating Score (0-4)
2.20
Research Coverage
5 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.50 billion

Miscellaneous

Free Float
106,758,000
Market Cap
$868.62 million
Optionable
Optionable
Beta
0.65

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. P. Gregory Garrison (Age 70)
    Executive Chairman of the Board
    Comp: $103k
  • Ms. Tejal Vakharia (Age 50)
    Senior VP of Marketing & Government Affairs, General Counsel and Chief Compliance Counsel
    Comp: $1.04M
  • Dr. Shih-Yin Ho M.B.A. (Age 53)
    M.D., Interim Chief Executive Officer & Director
  • Mr. Thomas J. Langan (Age 57)
    President & Chief Commercial Officer
  • Mr. Leland A. Westerfield (Age 54)
    Interim CFO and Principal Financial & Accounting Officer
  • Jenny Gelinas
    Vice President of Investor Relations
  • Mr. Richard Elmore
    Senior Vice President of Corporate Development & Strategy
  • Ms. Lisa Hammond C.P.C. (Age 51)
    Senior VP & Chief Human Resources Officer
  • Mr. John Sage
    Senior Vice President of U.S. Hospitals & Health Systems Sales
  • Mr. Elliot Bryant
    Senior VP & General Manager for Classic Client Solutions Business Unit

MDRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Veradigm stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veradigm in the last twelve months. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" MDRX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MDRX, but not buy additional shares or sell existing shares.
View MDRX analyst ratings
or view top-rated stocks.

What is Veradigm's stock price target for 2024?

5 analysts have issued 12 month price objectives for Veradigm's shares. Their MDRX share price targets range from $10.00 to $13.00. On average, they anticipate the company's share price to reach $11.25 in the next twelve months. This suggests a possible upside of 41.5% from the stock's current price.
View analysts price targets for MDRX
or view top-rated stocks among Wall Street analysts.

How have MDRX shares performed in 2024?

Veradigm's stock was trading at $10.49 at the start of the year. Since then, MDRX shares have decreased by 24.2% and is now trading at $7.95.
View the best growth stocks for 2024 here
.

How were Veradigm's earnings last quarter?

Veradigm Inc. (NASDAQ:MDRX) released its earnings results on Thursday, November, 4th. The software maker reported $0.27 earnings per share for the quarter, beating analysts' consensus estimates of $0.18 by $0.09. The software maker had revenue of $369 million for the quarter, compared to analysts' expectations of $376.09 million. The business's revenue was down 8.2% on a year-over-year basis. During the same quarter last year, the firm posted $0.15 EPS.

What is Paul Black's approval rating as Veradigm's CEO?

796 employees have rated Veradigm Chief Executive Officer Paul Black on Glassdoor.com. Paul Black has an approval rating of 65% among the company's employees.

What other stocks do shareholders of Veradigm own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Veradigm investors own include Advanced Micro Devices (AMD), Netflix (NFLX), Energy Transfer (ET), CVS Health (CVS), Ford Motor (F), Himax Technologies (HIMX), Intel (INTC), OPKO Health (OPK), Tesla (TSLA) and Activision Blizzard (ATVI).

Who are Veradigm's major shareholders?

Veradigm's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Meadow Creek Wealth Advisors LLC (0.01%). Insiders that own company stock include David B Stevens, Elaina Shekhter, Elizabeth Ann Altman, Greg Garrison, Leah Jones, Lisa Khorey, Michael Klayko, Paul Black, Richard J Poulton, Tejal Vakharia and Thomas Langan.
View institutional ownership trends
.

How do I buy shares of Veradigm?

Shares of MDRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Veradigm have any subsidiaries?
The following companies are subsidiares of Veradigm: HealthGrid, Practice Fusion, and ZappRx.
Read More
This page (NASDAQ:MDRX) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners